Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 12/20 | 0.69 |
| ▸ | GSK3B | P49841 | 12/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.48 |
| ▸ | IGF1R | P08069 | 5/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427365 | 0.88 | GSK3A (0.73) | GSK3AGSK3BNTRK1IGF1RFGFR1 | |
| SCHEMBL3384007 | 0.82 | GSK3B (1.00) | GSK3AGSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL3384147 | 0.70 | GSK3A (1.00) | GSK3AGSK3BMGLL | |
| SCHEMBL3382637 | 0.67 | GSK3A (1.00) | GSK3AGSK3BMGLL | |
| SCHEMBL4263923 | 0.66 | MGLL (0.73) | MGLL | |
| SCHEMBL3384854 | 0.66 | GSK3A (1.00) | GSK3AGSK3BMGLLCCNB2CDK1 | |
| SCHEMBL28477376 | 0.66 | KDM4E (0.61) | NTRK1IGF1RFGFR1NTRK2NTRK3 | |
| SCHEMBL21295403 | 0.65 | NTRK1 (1.00) | NTRK1IGF1RFGFR1NTRK2NTRK3 | |
| SCHEMBL27863634 | 0.65 | MGLL (0.71) | MGLL | |
| SCHEMBL27863609 | 0.65 | MGLL (0.71) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005024755-A2 | MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2005-03-17 | — | — | WO | disclosed |